Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Anixa Biosciences Inc is a diagnostics & research business based in the US. Anixa Biosciences shares (ANIX) are listed on the NASDAQ and all prices are listed in US Dollars. Anixa Biosciences employs 4 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $3.10 |
|---|---|
| 52-week range | $2.71 - $8.09 |
| 50-day moving average | $3.60 |
| 200-day moving average | $4.21 |
| Wall St. target price | $11.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.45 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.1 from 2022-01-21
| 1 week (2022-01-14) | -9.09% |
|---|---|
| 1 month (2021-12-23) | -2.52% |
| 3 months (2021-10-22) | -28.57% |
| 6 months (2021-07-23) | -27.06% |
| 1 year (2021-01-22) | -26.37% |
|---|---|
| 2 years (2020-01-24) | -19.69% |
| 3 years (2019-01-24) | 4.94 |
| 5 years (2017-01-24) | 4.85 |
| Revenue TTM | $512,500 |
|---|---|
| Gross profit TTM | $127,498 |
| Return on assets TTM | -35.92% |
| Return on equity TTM | -61.02% |
| Profit margin | 0% |
| Book value | $1.18 |
| Market capitalisation | $102.8 million |
TTM: trailing 12 months
We're not expecting Anixa Biosciences to pay a dividend over the next 12 months.
Anixa Biosciences's shares were split on a 1:25 basis on 25 June 2015. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Anixa Biosciences shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Anixa Biosciences shares which in turn could have impacted Anixa Biosciences's share price.
Over the last 12 months, Anixa Biosciences's shares have ranged in value from as little as $2.71 up to $8.09. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Anixa Biosciences's is 1.6685. This would suggest that Anixa Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Anixa Biosciences, Inc. , a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.